Effects of anti-diabetic drugs on bone metabolism

References

• IDF Diabetes Atlas. International Diabetes Federation. 6th Edition. International Diabetes Federation, Brussels, Belgium, 2013. Available from: www.idf.org/diabetesatlas [Last accessed 20 July 2015]
   Google Scholar
• Danielson KK, Elliott ME, LeCaire T, et al. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 2009;20:923-33
   PubMed Web of Science ®Google Scholar
• Tuominen JT, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999;22:1196-200
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011;305:2184-92
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007;18:427-44
   PubMed Web of Science ®Google Scholar
• Forsen L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920-5
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:45-55
   PubMed Web of Science ®Google Scholar
• Balint E, Szabo P, Marshall CF, et al. Glucose-induced inhibition of in vitro bone mineralization. Bone 2001;28:21-8
   PubMed Web of Science ®Google Scholar
• Nyomba BL, Verhaeghe J, Thomasset M, et al. Bone mineral homeostasis in spontaneously diabetic BB rats. I. Abnormal vitamin D metabolism and impaired active intestinal calcium absorption. Endocrinology 1989;124:565-72
   PubMed Web of Science ®Google Scholar
• Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006;17:1514-23
   PubMed Web of Science ®Google Scholar
• Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:195-201
   PubMed Web of Science ®Google Scholar
• Meier C, Schwartz AV, Egger A, et al. Effects of diabetes drugs on the skeleton. Bone 2015;S8756-3282(15):00139-8
   Google Scholar
• Montagnani A, Gonnelli S. Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 2013;15:784-91
   PubMed Web of Science ®Google Scholar
• WHO model list of essential medicines, World Health Organization. Department of Essential Medicines and Health Products, Geneva, Switzerland, 2015. Available from: www.who.int/entity/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_JUN2015.pdf [Last accessed 20 July 2015]
   Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69
   PubMed Web of Science ®Google Scholar
• Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696-704
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542-6
   PubMed Web of Science ®Google Scholar
• Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011;48:885-93
   PubMed Web of Science ®Google Scholar
• Jang WG, Kim EJ, Lee KN, et al. AMP-activated protein kinase (AMPK) positively regulates osteoblast differentiation via induction of Dlx5-dependent Runx2 expression in MC3T3E1 cells. Biochem Biophys Res Commun 2011;404:1004-9
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yano S, et al. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008;375:414-19
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim YS, Lee SY, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 2010;47:926-37
   PubMed Web of Science ®Google Scholar
• Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011;112:2902-9
   PubMed Web of Science ®Google Scholar
• Jeyabalan J, Viollet B, Smitham P, et al. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 2013;24:2659-70
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Livingstone SJ, Looker HC, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929-37
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 2010;28:554-60
   PubMed Web of Science ®Google Scholar
• Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199-203
   PubMed Web of Science ®Google Scholar
• Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014;57:2057-65
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5
   PubMed Web of Science ®Google Scholar
• Melton LJIII, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008;23:1334-42
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143:2376-84
   PubMed Web of Science ®Google Scholar
• Mieczkowska A, Basle MF, Chappard D, et al. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 2012;287:23517-26
   PubMed Web of Science ®Google Scholar
• Smith NJ, Stoddart LA, Devine NM, et al. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem 2009;284:17527-39
   PubMed Web of Science ®Google Scholar
• Stoddart LA, Brown AJ, Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5’-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 2007;71:994-1005
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6
   PubMed Web of Science ®Google Scholar
• Chappard D, Marchand-Libouban H, Moreau MF, et al. Thiazolidinediones cause compaction of nuclear heterochromatin in the pluripotent mesenchymal cell line C3H10T1/2 when inducing an adipogenic phenotype. Anal Quant Cytopathol Histpathol 2013;35:85-94
   PubMed Web of Science ®Google Scholar
• Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999;140:5060-5
   PubMed Web of Science ®Google Scholar
• Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-16
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Mieczkowska A, Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 2010;27:925-32
   PubMed Web of Science ®Google Scholar
• Yamato H, Okazaki R, Ishii T, et al. Effect of 24R,25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells. Calcif Tissue Int 1993;52:255-60
   PubMed Web of Science ®Google Scholar
• Chan BY, Gartland A, Wilson PJ, et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007;40:149-59
   PubMed Web of Science ®Google Scholar
• Mbalaviele G, Abu-Amer Y, Meng A, et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000;275:14388-93
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007;177:723-4
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30
   PubMed Web of Science ®Google Scholar
• Ton FN, Gunawardene SC, Lee H, et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464-70
   PubMed Web of Science ®Google Scholar
• Kolli V, Stechschulte LA, Dowling AR, et al. Partial agonist, telmisartan, maintains PPARgamma serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. PLoS One 2014;9:e96323
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Suva LJ, et al. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006;38:74-84
   PubMed Web of Science ®Google Scholar
• Lee DH, Huang H, Choi K, et al. Selective PPARgamma modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab 2012;302:E552-60
   PubMed Web of Science ®Google Scholar
• Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996;28:456-63
   PubMed Web of Science ®Google Scholar
• Ma P, Gu B, Ma J, et al. Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism 2010;59:359-66
   PubMed Web of Science ®Google Scholar
• Ma P, Xiong W, Liu H, et al. Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: Regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway. Arch Oral Biol 2011;56:307-16
   PubMed Web of Science ®Google Scholar
• Fronczek-Sokol J, Pytlik M. Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats. Pharmacol Rep 2014;66:412-17
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169:1395-402
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-9
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol 2011;11:12
   PubMedGoogle Scholar
• Nuche-Berenguer B, Portal-Nunez S, Moreno P, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010;225:585-92
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Mieczkowska A, Irwin N, et al. Optimal bone mechanical and material properties require a functional GLP-1 receptor. J Endocrinol 2013;219:59-68
   PubMed Web of Science ®Google Scholar
• Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008;149:574-9
   PubMed Web of Science ®Google Scholar
• Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012;153:1538-47
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003;18:2180-9
   PubMed Web of Science ®Google Scholar
• Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009;84:453-61
   PubMed Web of Science ®Google Scholar
• Nuche-Berenguer B, Moreno P, Portal-Nunez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2010;159:61-6
   PubMed Web of Science ®Google Scholar
• Ma X, Meng J, Jia M, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 2013;28:1641-52
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee SK, Jo KJ, et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 2013;92:533-40
   PubMed Web of Science ®Google Scholar
• Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine 2015;48:107-15
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 2014;6:260-6
   PubMed Web of Science ®Google Scholar
• Driessen JH, Henry RM, van Onzenoort HA, et al. Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis. Calcif Tissue Int 2015;68:124-30
   Google Scholar
• Sbaraglini ML, Molinuevo MS, Sedlinsky C, et al. Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. Eur J Pharmacol 2014;727:8-14
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, Sun H, Kornhauser C, et al. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev 2014;30:191-200
   PubMed Web of Science ®Google Scholar
• Kyle KA, Willett TL, Baggio LL, et al. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011;152:457-67
   PubMed Web of Science ®Google Scholar
• Cusick T, Mu J, Pennypacker BL, et al. Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Diabetes Obes Metab 2013;15:954-7
   PubMed Web of Science ®Google Scholar
• Glorie L, Behets GJ, Baerts L, et al. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab 2014;307:E447-55
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34:2474-6
   PubMed Web of Science ®Google Scholar
• Driessen JH, van Onzenoort HA, Henry RM, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone 2014;68:124-30
   PubMed Web of Science ®Google Scholar
• Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer’s disease? Expert Opin Investig Drugs 2010;19:1039-48
   PubMed Web of Science ®Google Scholar
• McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009;80:409-71
   PubMed Web of Science ®Google Scholar
• Maida A, Hansotia T, Longuet C, et al. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009;137:2146-57
   PubMed Web of Science ®Google Scholar
• Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000;141:1228-35
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Mieczkowska A, Irwin N, et al. Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties. Bone 2014;63:61-8
   PubMed Web of Science ®Google Scholar
• Mansur SA, Mieczkowska A, Bouvard B, et al. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus. J Cell Physiol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gaudin-Audrain C, Irwin N, Mansur S, et al. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone 2013;53:221-30
   PubMed Web of Science ®Google Scholar
• Mieczkowska A, Irwin N, Flatt PR, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone 2013;56:337-42
   PubMed Web of Science ®Google Scholar
• Mabilleau G. Incretins and bone: friend or foe? Curr Opin Pharmacol 2015;22:72-8
   PubMed Web of Science ®Google Scholar
• Pathak V, Vasu S, Flatt PR, et al. Effects of chronic exposure of clonal beta-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1. Diabetes Obes Metab 2014;16:357-65
   PubMed Web of Science ®Google Scholar
• Hojberg PV, Vilsboll T, Zander M, et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med 2008;25:1268-75
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Bryer-Ash M, Elahi D. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 1993;16:110-14
   PubMed Web of Science ®Google Scholar
• Nissen A, Christensen M, Knop FK, et al. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 2014;99:E2325-9
   PubMed Web of Science ®Google Scholar
• Torekov SS, Harslof T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014;99:E729-33
   PubMed Web of Science ®Google Scholar
• Bergstrom WH, Wallace WM. Bone as a sodium and potassium reservoir. J Clin Invest 1954;33:867-73
   PubMed Web of Science ®Google Scholar
• Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 2011;286:10864-75
   PubMed Web of Science ®Google Scholar
• Hannon MJ, Verbalis JG. Sodium homeostasis and bone. Curr Opin Nephrol Hypertens 2014;23:370-6
   PubMed Web of Science ®Google Scholar
• Tamma R, Sun L, Cuscito C, et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci USA 2013;110:18644-9
   PubMed Web of Science ®Google Scholar
• Nordin BE, Need AG, Morris HA, et al. The nature and significance of the relationship between urinary sodium and urinary calcium in women. J Nutr 1993;123:1615-22
   PubMed Web of Science ®Google Scholar
• Tirmenstein M, Dorr TE, Janovitz EB, et al. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 2013;32:336-50
   PubMed Web of Science ®Google Scholar
• Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71
   PubMed Web of Science ®Google Scholar
• Canagliflozin: clinical efficacy and safety. FDA Public Health Advisory. FDA/Center fro Drug Evaluation and Research, Silver Spring, MA, 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM336234.pdf [Last accessed 20 July 2015]
   Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3:8-10
   PubMed Web of Science ®Google Scholar
• Gault VA, Bhat VK, Irwin N, et al. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem 2013;288:35581-91
   PubMed Web of Science ®Google Scholar
• Irwin N, Pathak V, Flatt PR. A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering and satiety actions with significant therapeutic potential in high-fat fed mice. Diabetes 2015;64(8):2996-3009
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia 2015;58(8):1745-50
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• The management of type 2 diabetes. National Institute for Health and Care Excellence. National Institute for Health and Care Excellence, London, UK, 2009. Available from: www.nice.org.uk/guidance/cg87 [Last accessed 20 July 2015]
   Google Scholar